NOIDA, India -- The miRNA market in the Americas was estimated to be around US$ 85 Million in 2013, and is likely to reach US$ 204 Million by 2018. The growth can be attributed to the active research environment of the country, generous funding and support provided by the regulatory authorities, and high standards of research infrastructure and intellect.
The report “Global miRNA Market Outlook to 2018”, covers present and future outlook for the two broad categories of miRNA; the tools and services segments. The former comprises of the various tools that are used to study miRNA. These include isolation kits, PCR arrays, labels, markers, mimics and inhibitors. On the other hand, the latter includes the various services such as purification, expression profiling, quantitation and analysis that are offered by miRNA players. The market has been divided into three sections i.e., The Americas, Europe and Asia Pacific. These regions have then been analyzed to draw patterns in terms of research areas and applicability. A brief look at the market suggests that cancer is the most researched topic and regions such as United States, United Kingdom, France, Israel and China are the major players interested in evaluating the role played by miRNA.
Most of the current research is focused on utilizing miRNA for diagnostic purposes such as expression profiling, response evaluation and setting potential biomarkers in diseases. Another application is in the field of therapeutics where miRNA mimics and inhibitors are being applied to control gene translation and consequently its expression.
After an exhaustive study of the industry, RNCOS has laid out the primary market players which engaged in providing miRNA based tools and services. These players are working over a vast variety of products such as miRNA extraction and purification kits, and miRNA mimics and inhibitors. Some of them include Qiagen, Life Technologies, Exiqon and Mirus Bio.
And More Visit:- http://www.rncos.com/Market-Analysis-Reports/Global-miRNA...
Media Contact
Rncos
0120 4224700
